SonoThera raised $125 million in a Series B to advance an ultrasound-based non-viral gene delivery platform toward clinical development. The funding includes participation from venture firms and pharma venture arms, including UCB, Bayer, Otsuka, and Johnson & Johnson. The company’s lead programs target Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease, with plans to push candidates into the clinic. The approach relies on microbubbles activated by ultrasound to deliver nucleic acids to tissues, aiming to address common delivery constraints seen with viral vectors and traditional lipid nanoparticles. SonoThera’s narrative emphasizes repeatability and scalability of delivery, which can be a differentiator for gene therapies intended for broader populations. The technology origin traces back to contrast ultrasound microbubble development. As more gene-therapy platforms compete on safety, dosing cadence, and manufacturing complexity, the Series B highlights continued investor willingness to fund alternative delivery modalities with clear clinical translational pathways.